Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China Completes Largest Ever Dry Eye Disease Clinical Trial
Details : The patient group receiving CsA Ophthalmic Gel (0.05%, q.d.) has demonstrated statistically significant (P<0.0001) and clinically meaningful improvements in ICSS compared to the patient group receiving a comparator treatment.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
August 18, 2021
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Nevakar
Deal Size : $102.0 million
Deal Type : Licensing Agreement
Details :
Product Name : NVK002
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 20, 2020
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Nevakar
Deal Size : $102.0 million
Deal Type : Licensing Agreement